Search

Your search keyword '"Parisi,Alessandro"' showing total 9 results
Start Over Author "Parisi,Alessandro" Journal cancers
9 results on '"Parisi,Alessandro"'

1. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

Author

Turinetto, Margherita, primary, Ricotti, Andrea, additional, Marchetti, Claudia, additional, Pisano, Carmela, additional, Zamagni, Claudio, additional, Cassani, Chiara, additional, Malaguti, Paola, additional, Baldoni, Alessandra, additional, Scollo, Paolo, additional, Scandurra, Giuseppa, additional, Parisi, Alessandro, additional, Artioli, Grazia, additional, Palaia, Innocenza, additional, Vertechy, Laura, additional, Bergamini, Alice, additional, Picardo, Elisa, additional, Tuninetti, Valentina, additional, Scotto, Giulia, additional, Scambia, Giovanni, additional, Pignata, Sandro, additional, and Valabrega, Giorgio, additional

Published
2023
Full Text
View/download PDF

2. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

Author

Turinetto, Margherita, Ricotti, Andrea, Marchetti, Claudia, Pisano, Carmela, Zamagni, Claudio, Cassani, Chiara, Malaguti, Paola, Baldoni, Alessandra, Scollo, Paolo, Scandurra, Giuseppa, Parisi, Alessandro, Artioli, Grazia, Palaia, Innocenza, Vertechy, Laura, Bergamini, Alice, Picardo, Elisa, Tuninetti, Valentina, Scotto, Giulia, Scambia, Giovanni, and Pignata, Sandro

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, RESEARCH, DISEASE progression, HAND-foot syndrome, OVARIAN tumors, SCIENTIFIC observation, CONFIDENCE intervals, DOXORUBICIN, RESEARCH methodology, CASE-control method, RETROSPECTIVE studies, GASTROINTESTINAL diseases, PLATINUM, BLOOD diseases, DESCRIPTIVE statistics, RESEARCH funding, FATIGUE (Physiology), ENZYME inhibitors, EVALUATION
Abstract

Simple Summary: This multicenter, retrospective analysis had the objective of comparing the efficacy of PLD-Trabectedin in patients who had already been treated with PARP-I (cases) before vs. PARPi-naïve patients (controls). Data from 166 patients were collected, composed of 109 cases and 57 controls. In total, 135 patients were included in our analyses, composing 46 controls and 89 cases. We found a median PFS of 11 months (95% IC 10–12) in the control group vs. 8 months (95% IC 6–9) in the case group (p value 0.0017). The clinical benefit rate was evaluated, with an HR for progression of 2.55 (1.28–5.06) for the case group (p value 0.008) persisting when adjusted for BRCA mutation. The study showed a statistically significant difference in terms of PFS, suggesting that a previous exposure to PARP-i might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted. Objective: While PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, its efficacy and tolerability has so far not been tested extensively in patients who progress after poly ADP-ribose polymerase inhibitor (PARPi) treatment. Methodology: This multicenter, retrospective analysis had the objective of comparing patients receiving PLD-Trabectedin after being treated with PARP-I (cases) with PARPi-naïve patients. Descriptive and survival analyses were performed for each group. Results: Data from 166 patients were collected, composed of 109 cases and 57 controls. In total, 135 patients were included in our analyses, composing 46 controls and 89 cases. The median PFS was 11 months (95% IC 10–12) in the control group vs. 8 months (95% IC 6–9) in the case group (p value 0.0017). The clinical benefit rate was evaluated, with an HR for progression of 2.55 (1.28–5.06) for the case group (p value 0.008), persisting when adjusted for BRCA and line with treatment. We compared hematological toxicity, gastro-intestinal toxicity, hand–foot syndrome (HFS), fatigue, and liver toxicity, and no statistically significant disparity was noted, except for HFS with a p value of 0.006. The distribution of G3 and G4 toxicities was also equally represented. Conclusion: The MITO39 study showed a statistically significant difference in terms of PFS, suggesting that previous exposure to PARPi might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted; PLD-Trabectedin was confirmed to be a well-tolerated scheme in both groups. To our knowledge, these are the first data regarding this topic, which we deem to be of great relevance in the current landscape. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study

Author

Tuninetti, Valentina, primary, Ghisoni, Eleonora, additional, Pignata, Sandro, additional, Picardo, Elisa, additional, Raspagliesi, Francesco, additional, Andreetta, Claudia, additional, Maldi, Elena, additional, Artioli, Grazia, additional, Mammoliti, Serafina, additional, Zanchi, Lucia, additional, Sikokis, Angelica, additional, Biglia, Nicoletta, additional, Parisi, Alessandro, additional, Mandato, Vincenzo Dario, additional, Carella, Claudia, additional, Cormio, Gennaro, additional, Marinaccio, Marco, additional, Puppo, Andrea, additional, Paolini, Biagio, additional, Borsotti, Lucia, additional, Scotto, Giulia, additional, Turinetto, Margherita, additional, Sangiolo, Dario, additional, Di Maio, Massimo, additional, and Valabrega, Giorgio, additional

Published
2023
Full Text
View/download PDF

4. Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study

Author

Granieri, Stefano, primary, Cotsoglou, Christian, additional, Bonomi, Alessandro, additional, Salvatore, Lisa, additional, Filippi, Roberto, additional, Nigro, Olga, additional, Gelsomino, Fabio, additional, Zurlo, Ina Valeria, additional, Depetris, Ilaria, additional, Giampieri, Riccardo, additional, Berardi, Rossana, additional, Morelli, Cristina, additional, De Tursi, Michele, additional, Roberto, Michela, additional, Gjoni, Elson, additional, Germini, Alessandro, additional, de Angelis, Nicola, additional, Memeo, Riccardo, additional, Facciorusso, Antonio, additional, Garrone, Ornella, additional, Ramai, Daryl, additional, Ghidini, Michele, additional, and Parisi, Alessandro, additional

Published
2022
Full Text
View/download PDF

5. Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status

Author

Irelli, Azzurra, primary, Parisi, Alessandro, additional, D’Orazio, Carla, additional, Sidoni, Tina, additional, Rotondaro, Silvia, additional, Patruno, Leonardo, additional, Pavese, Francesco, additional, Bafile, Alberto, additional, Resta, Valter, additional, Pizzorno, Laura, additional, Ciuffetelli, Virginia, additional, Dalmas, Antonella, additional, Calvisi, Giuseppe, additional, Di Sibio, Alessandra, additional, Marzullo, Anna, additional, Zelli, Veronica, additional, Compagnoni, Chiara, additional, Tessitore, Alessandra, additional, Alesse, Edoardo, additional, Ficorella, Corrado, additional, Cortellini, Alessio, additional, and Cannita, Katia, additional

Published
2022
Full Text
View/download PDF

7. Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer

Author

Roberto, Michela, primary, Arrivi, Giulia, additional, Lo Bianco, Francesca, additional, Cascinu, Stefano, additional, Gelsomino, Fabio, additional, Caputo, Francesco, additional, Cerma, Krisida, additional, Ghidini, Michele, additional, Ratti, Margherita, additional, Pizzo, Claudio, additional, Ficorella, Corrado, additional, Parisi, Alessandro, additional, Cortellini, Alessio, additional, Urbano, Federica, additional, Calandrella, Maria Letizia, additional, Dell’Aquila, Emanuela, additional, Minelli, Alessandro, additional, Fulgenzi, Claudia Angela Maria, additional, Gariazzo, Ludovica, additional, Montori, Andrea, additional, Pilozzi, Emanuela, additional, Di Girolamo, Marco, additional, Marchetti, Paolo, additional, and Mazzuca, Federica, additional

Published
2020
Full Text
View/download PDF

8. Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Author

Parisi, Alessandro, primary, Cortellini, Alessio, additional, Cannita, Katia, additional, Venditti, Olga, additional, Camarda, Floriana, additional, Calegari, Maria Alessandra, additional, Salvatore, Lisa, additional, Tortora, Giampaolo, additional, Rossini, Daniele, additional, Germani, Marco Maria, additional, Boccaccino, Alessandra, additional, Dell’Aquila, Emanuela, additional, Fulgenzi, Claudia, additional, Santini, Daniele, additional, De Tursi, Michele, additional, Tinari, Nicola, additional, Di Marino, Pietro, additional, Lombardi, Pasquale, additional, Roselló Keränen, Susana, additional, Huerta Álvaro, Marisol, additional, Zurlo, Ina Valeria, additional, Corsi, Domenico Cristiano, additional, Emiliani, Alessandra, additional, Zanaletti, Nicoletta, additional, Troiani, Teresa, additional, Vitale, Pasquale, additional, Giampieri, Riccardo, additional, Merloni, Filippo, additional, Occhipinti, Mario Alberto, additional, Marchetti, Paolo, additional, Roberto, Michela, additional, Mazzuca, Federica, additional, Ghidini, Michele, additional, Indini, Alice, additional, Garajova, Ingrid, additional, Zoratto, Federica, additional, Delle Monache, Simona, additional, Porzio, Giampiero, additional, and Ficorella, Corrado, additional

Published
2020
Full Text
View/download PDF

9. Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients

Author

Rastrelli, Marco, primary, Ferrazzi, Beatrice, additional, Cavallin, Francesco, additional, Chiarion Sileni, Vanna, additional, Pigozzo, Jacopo, additional, Fabozzi, Alessio, additional, Tropea, Saveria, additional, Vecchiato, Antonella, additional, Costa, Alessandra, additional, Parisi, Alessandro, additional, Rossi, Carlo, additional, Del Fiore, Paolo, additional, and Alaibac, Mauro, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results